Target Price | $38.50 |
Price | $35.63 |
Potential | 8.06% |
Number of Estimates | 16 |
16 Analysts have issued a price target Keurig Dr Pepper Inc 2026 . The average Keurig Dr Pepper Inc target price is $38.50. This is 8.06% higher than the current stock price. The highest price target is $42.00 17.88% , the lowest is $34.00 4.57% . | |
A rating was issued by 20 analysts: 11 Analysts recommend Keurig Dr Pepper Inc to buy, 9 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Keurig Dr Pepper Inc stock has an average upside potential 2026 of 8.06% . Most analysts recommend the Keurig Dr Pepper Inc stock at Purchase. |
14 Analysts have issued a sales forecast Keurig Dr Pepper Inc 2025 . The average Keurig Dr Pepper Inc sales estimate is $16.1b . This is 5.03% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $16.4b 6.63% , the lowest is $15.8b 3.04% .
This results in the following potential growth metrics:
2024 | $15.4b | 3.62% |
---|---|---|
2025 | $16.1b | 5.03% |
2026 | $16.8b | 3.99% |
2027 | $17.4b | 3.89% |
2028 | $17.8b | 2.06% |
11 Analysts have issued an Keurig Dr Pepper Inc EBITDA forecast 2025. The average Keurig Dr Pepper Inc EBITDA estimate is $4.9b . This is 13.22% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $5.0b 16.61% , the lowest is $4.7b 9.30% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.3b | 9.68% |
---|---|---|
2025 | $4.9b | 13.11% |
2026 | $5.1b | 4.96% |
2027 | $5.4b | 4.97% |
2028 | $5.3b | 0.45% |
2024 | 28.04% | 5.84% |
---|---|---|
2025 | 30.20% | 7.69% |
2026 | 30.48% | 0.93% |
2027 | 30.80% | 1.05% |
2028 | 30.04% | 2.47% |
6 Keurig Dr Pepper Inc Analysts have issued a net profit forecast 2025. The average Keurig Dr Pepper Inc net profit estimate is $2.7b . This is 87.06% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.8b 94.52% , the lowest is $2.5b 72.38% .
This results in the following potential growth metrics and future Net Margins:
2024 | $1.4b | 32.26% |
---|---|---|
2025 | $2.7b | 87.06% |
2026 | $2.9b | 8.65% |
2027 | $3.1b | 6.62% |
2028 | $3.4b | 9.51% |
2024 | 9.28% | 34.63% |
---|---|---|
2025 | 16.53% | 78.13% |
2026 | 17.27% | 4.48% |
2027 | 17.72% | 2.61% |
2028 | 19.01% | 7.28% |
6 Analysts have issued a Keurig Dr Pepper Inc forecast for earnings per share. The average Keurig Dr Pepper Inc EPS is $1.96 . This is 86.67% higher than earnings per share in the financial year 2024. The highest EPS forecast is $2.04 94.29% , the lowest is $1.81 72.38% .
This results in the following potential growth metrics and future valuations:
2024 | $1.05 | 32.26% |
---|---|---|
2025 | $1.96 | 86.67% |
2026 | $2.13 | 8.67% |
2027 | $2.28 | 7.04% |
2028 | $2.49 | 9.21% |
Current | 33.88 | 71.20% |
---|---|---|
2025 | 18.14 | 46.46% |
2026 | 16.70 | 7.94% |
2027 | 15.66 | 6.23% |
2028 | 14.30 | 8.68% |
Based on analysts' sales estimates for 2025, the Keurig Dr Pepper Inc stock is valued at an EV/Sales of 4.04 and an P/S ratio of 3.00 .
This results in the following potential growth metrics and future valuations:
Current | 4.24 | 9.84% |
---|---|---|
2025 | 4.04 | 4.82% |
2026 | 3.88 | 3.84% |
2027 | 3.74 | 3.75% |
2028 | 3.66 | 2.02% |
Current | 3.15 | 9.61% |
---|---|---|
2025 | 3.00 | 4.78% |
2026 | 2.88 | 3.84% |
2027 | 2.78 | 3.75% |
2028 | 2.72 | 2.02% |
Keurig Dr Pepper Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Morgan Stanley |
Equal-Weight
➜
Overweight
|
Upgrade | Apr 01 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Feb 27 2025 |
JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Feb 26 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Feb 26 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Jan 17 2025 |
UBS |
Buy
➜
Buy
|
Unchanged | Jan 16 2025 |
TD Cowen |
Hold
➜
Hold
|
Unchanged | Jan 08 2025 |
Analyst Rating | Date |
---|---|
Upgrade
Morgan Stanley:
Equal-Weight
➜
Overweight
|
Apr 01 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Feb 27 2025 |
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Feb 26 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Feb 26 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Jan 17 2025 |
Unchanged
UBS:
Buy
➜
Buy
|
Jan 16 2025 |
Unchanged
TD Cowen:
Hold
➜
Hold
|
Jan 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.